Role of ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease

World Journal of Surgery

Volumn 38, Issue 6, 2014, Pages 1353-1361

  Miller, H C ^a   Drymousis, P ^a   Flora, R ^a   Goldin, R ^a   Spalding, D ^a   Frilling, A ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; TUMOR MARKER;

ADULT; AGED; CANCER GRADING; CANCER STAGING; COHORT ANALYSIS; COMPARATIVE STUDY; DIGESTIVE SYSTEM NEOPLASMS; DISEASE FREE SURVIVAL; EVALUATION STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MALE; METABOLISM; MIDDLE AGED; MITOSIS INDEX; MORTALITY; NEEDLE BIOPSY; NEUROENDOCRINE TUMORS; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; ROLE PLAYING; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR INVASION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; COHORT STUDIES; DIGESTIVE SYSTEM NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPH NODES; MALE; MIDDLE AGED; MITOTIC INDEX; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; ROLE; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84902198500     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-014-2451-0     Document Type: Article

References (55)

1. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM (2011) The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 40(1):1-18 vii
2. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE et al (2008) One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26(18):3063-3072
3. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Diaz-Perez JA, Martinez Del Prado MP, Alonso Orduna V et al (2010) Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 21(9):1794-1803
4. Lombard-Bohas C, Mitry E, O'Toole D, Louvet C, Pillon D, Cadiot G et al (2009) Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France. Neuroendocrinology 89(2):217-222
5. Ahmed A, Turner G, King B, Jones L, Culliford D, McCance D et al (2009) Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer 16(3):885-894
6. Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B (2008) Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Research 14(23):7798-7803
7. Jann H, Roll S, Couvelard A, Hentic O, Pavel M, Muller-Nordhorn J et al (2011) Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer 117(15):3332-3341
8. Rindi G, Falconi M, Klersy C, Albarello L, Boninsegna L, Buchler MW et al (2012) TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 104(10):764-777
9. Beasley MB, Thunnissen FB, Brambilla E, Hasleton P, Steele R, Hammar SP et al (2000) Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol 31(10):1255-1265
10. Hotta K, Shimoda T, Nakanishi Y, Saito D (2006) Usefulness of Ki-67 for predicting the metastatic potential of rectal carcinoids. Pathol Int 56(10):591-596
11. Jamali M, Chetty R (2008) Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining. Endocr Pathol 19(4):282-288
12. Rindi G, Kloppel G, Ahlman H, Caplin M, Couvelard A, de Herder WW et al (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449(4):395-401
13. Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes JM et al (2007) TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451(4):757-762
14. Bosman FT, World Health Organization, International Agency for Research on Cancer (2010) WHO classification of tumours of the digestive system, 4th edn. International Agency for Research on Cancer, Lyon, p 417
15. Khan MS, Luong TV, Watkins J, Toumpanakis C, Caplin ME, Meyer T (2013) A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms. Br J Cancer 108(9):1838-1845
16. Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R et al (2010) Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 23(6):824-833
17. Hentic O, Couvelard A, Rebours V, Zappa M, Dokmak S, Hammel P et al (2011) Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas. Endocr Relat Cancer 18(1):51-59
18. Boninsegna L, Panzuto F, Partelli S, Capelli P, Delle Fave G, Bettini R et al (2012) Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. Eur J Cancer 48(11):1608-1615
19. Dhall D, Mertens R, Bresee C, Parakh R, Wang HL, Li M et al (2012) Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors. Hum Pathol 43(4):489-495
20. La Rosa S, Klersy C, Uccella S, Dainese L, Albarello L, Sonzogni A et al (2009) Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol 40(1):30-40
21. Durante C, Boukheris H, Dromain C, Duvillard P, Leboulleux S, Elias D et al (2009) Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer 16(2):585-597
22. Haug AR, Cindea-Drimus R, Auernhammer CJ, Reincke M, Wangler B, Uebleis C et al (2012) The role of 68 Ga-DOTATATE PET/CT in suspected neuroendocrine tumors. J Nucl Med 53(11):1686-1692
23. Frilling A, Sotiropoulos GC, Radtke A, Malago M, Bockisch A, Kuehl H et al (2010) The impact of 68 Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg 252(5):850-856
24. Baum RP, Kulkarni HR, Carreras C (2012) Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms. Semin Nucl Med 42(3):190-207
25. Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T et al (2012) ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95(2):157-176
26. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514-523
27. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364(6):501-513
28. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27(28):4656-4663
29. Pape UF, Berndt U, Muller-Nordhorn J, Bohmig M, Roll S, Koch M et al (2008) Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 15(4):1083-1097
30. Panzuto F, Boninsegna L, Fazio N, Campana D, Pia Brizzi M, Capurso G et al (2011) Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol 29(17):2372-2377
31. Landerholm K, Zar N, Andersson RE, Falkmer SE, Jarhult J (2011) Survival and prognostic factors in patients with small bowel carcinoid tumour. Br J Surg 98(11):1617-1624
32. Norlen O, Stalberg P, Oberg K, Eriksson J, Hedberg J, Hessman O et al (2012) Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg 36(6):1419-1431. doi: 10.1007/s00268-011-1296-z
33. Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S et al (2005) Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 12(4):1083-1092
34. Ruf J, Heuck F, Schiefer J, Denecke T, Elgeti F, Pascher A et al (2010) Impact of multiphase 68 Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology 91(1):101-109
35. Frilling A, Li J, Malamutmann E, Schmid KW, Bockisch A, Broelsch CE (2009) Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg 96(2):175-184
36. Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, Kwekkeboom D, Lau WY, Klersy C, Vilgrain V, Davidson B, Siegler M, Caplin M, Solcia E, Schilsky R, Working Group Neuroendocrine Metastasis (2014) Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 15(1):e8-e21
37. Yang Z, Tang LH, Klimstra DS (2011) Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol 35(6):853-860
38. Couvelard A, Deschamps L, Ravaud P, Baron G, Sauvanet A, Hentic O et al (2009) Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors. Mod Pathol 22(2):273-281
39. Remes SM, Tuominen VJ, Helin H, Isola J, Arola J (2012) Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices. Am J Surg Pathol 36(9):1359-1363
40. Tang LH, Gonen M, Hedvat C, Modlin IM, Klimstra DS (2012) Objective quantification of the Ki-67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol 36(12):1761-1770
41. Young HT, Carr NJ, Green B, Tilley C, Bhargava V, Pearce N (2013) Accuracy of visual assessments of proliferation indices in gastroenteropancreatic neuroendocrine tumours. J Clin Pathol 66(8):700-704
42. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA et al (2010) The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467(7319):1109-1113
43. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J et al (2011) Tumour evolution inferred by single-cell sequencing. Nature 472(7341):90-94
44. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10):883-892
45. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW et al (2010) Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464(7291):999-1005
46. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B et al (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467(7319):1114-1147
47. Habal N, Sims C, Bilchik AJ (2000) Gastrointestinal carcinoid tumors and second primary malignancies. J Surg Oncol 75(4):310-316
48. Kothari T, Mangla JC (1981) Malignant tumors associated with carcinoid tumors of the gastrointestinal tract. J Clin Gastroenterol 3(Suppl 1):43-46
49. Kim JY, Jang WY, Heo MH, Lee KK, Do YR, Park KU et al (2012) Metachronous double primary cancer after diagnosis of gastric cancer. Cancer Res Treat 44(3):173-178
50. Liu L, Lemmens VE, De Hingh IH, de Vries E, Roukema JA, van Leerdam ME et al (2013) Second primary cancers in subsites of colon and rectum in patients with previous colorectal cancer. Dis Colon Rectum 56(2):158-168
51. Watanabe M, Kochi M, Fujii M, Kaiga T, Mihara Y, Funada T et al (2012) Dual primary gastric and colorectal cancer: is the prognosis better for synchronous or metachronous? Am J Clin Oncol 35(5):407-410
52. Schimmack S, Svejda B, Lawrence B, Kidd M, Modlin IM (2011) The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbecks Arch Surg 396(3):273-298
53. Zucker KA, Longo WE, Modlin IM, Bilchik AJ, Adrian TE (1989) Malignant diathesis from jejunal-ileal carcinoids. Am J Gastroenterol 84(2):182-186
54. Reubi JC, Gugger M, Waser B, Schaer JC (2001) Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res 61(11):4636-4641
55. Chave HS, Gough AC, Palmer K, Preston SR, Primrose JN (2000) Bombesin family receptor and ligand gene expression in human colorectal cancer and normal mucosa. Br J Cancer 82(1):124-130